Pacific Edge Limited (PEB) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everybody, and welcome to the Pacific Edge 1H financial results presentation. I'm Pacific Edge's CEO, Dr. Peter Matius, and with me today is Grant Gibson, our CFO, and available online for questions is our chairman, Chris Gallagher. Just an important notice to take notice of when considering the information in today's presentation. So our financial results for this half are below our expectations. We ran fewer tests than we had desired. We ran fewer commercial tests than desired, and our operating revenue is down. However, we maintain that we are in the strongest strategic position yet, and despite a net loss of $19.1 billion and cash of $22.1 million in the bank, We want to highlight for investors the importance of the strategic milestones that we have managed to achieve through this hunt. And we've managed to do this maintaining a US market presence to position ourselves to successfully appeal Medicare tests and commercial tests. And so while there have been some challenges associated with non-coverage determination being the predominant feature of operating the market, and we have had to migrate our customers from triage to detect, Our US sales per FTE, you know, has maintained its... Our sales force efficiency has been maintained, and we are operating as well as we can under the circumstances. Most importantly, though, we have an expert contractor advisory committee, a CAC, or a CAC, that has been convened by Novitas for February 19 in 2026. And this acknowledges the weight of the evidence behind urine-based biomarkers for hematuria evaluation in general, of course driven by the evidence portfolio of CX bladder. We also in the half achieved an absolutely critical milestone with longer-term economics for TriagePlus being locked in at US$1,328 per tes...